GeoVax Labs(GOVX) - 2024 Q4 - Annual Results

Exhibit 99.1 GeoVax Reports 2024 Year-End Financial Results and Provides Business Update GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed Additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in first half of 2025 Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to begin in second half of 2025 Planning underway for ...